EFFICACY AND SAFETY OF ZOLEDRONIC ACID 5 MG IN THE PREVENTION OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN WITH OSTEOPENIA: THE HORIZON PREVENTION STUDY

被引：0
|
作者：
McClung, Michael R. [1 ]
Miller, Paul [2 ]
Recknor, Christopher [3 ]
Ruzucky, Maryellen [4 ]
BucciRechtweg, Christina [4 ]
Yu, Sue [4 ]
Benhamou, Claude Laurent [5 ]
机构：
[1] Oregon Osteoporosis Ctr, Portland, OR USA
[2] Colorado Ctr Bone Res, Lakewood, CO USA
[3] UOC, Gainesville, FL USA
[4] Novartis Pharmaceut, E Hanover, NJ USA
[5] IPROSA Reg Hosp Orleans, Orleans, France
来源：
OSTEOPOROSIS INTERNATIONAL | 2009年 / 20卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：S212 / S213
页数：2
相关论文
共 50 条
  • [31] ESTROGENS IN THE PREVENTION OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN
    GENANT, HK
    BAYLINK, DJ
    GALLAGHER, JC
    [J]. AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 1989, 161 (06) : 1842 - 1846
  • [32] Alphacalcidol in osteoporosis prevention in postmenopausal women
    Nikitinskaya, OA
    Benevolenskaya, LI
    [J]. BONE, 2001, 28 (05) : S243 - S243
  • [33] PREVENTION OF OSTEOPOROSIS IN PREMENOPAUSAL AND POSTMENOPAUSAL WOMEN
    SAGRAVES, R
    [J]. AMERICAN JOURNAL OF PHARMACEUTICAL EDUCATION, 1991, 55 (02) : 158 - 166
  • [34] PREVENTION AND MANAGEMENT OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN
    Nematollahi, A.
    Montaseri, Z.
    Yazdanpanahi, Z.
    [J]. OSTEOPOROSIS INTERNATIONAL, 2010, 21 : S755 - S756
  • [35] Effect of zoledronic acid (ZOL) 5 mg on fracture risk by age and geographic region in women with postmenopausal osteoporosis: Results from horizon-PFT
    Cauley, Jane A.
    Black, Dennis
    Boonen, Steven R.
    Cummings, Steven
    Delmas, Pierre
    Eastell, Richard
    [J]. OSTEOPOROSIS INTERNATIONAL, 2007, 18 : S232 - S232
  • [36] Effect of Zoledronic Acid (ZOL) 5 mg on fracture risk by age and geographic region in women with postmenopausal osteoporosis: results from HORIZON-PFT
    Cauley, J.
    Black, D.
    Boonen, S.
    Cummings, S.
    Delmas, P.
    Eastell, R.
    [J]. OSTEOPOROSIS INTERNATIONAL, 2007, 18 : S26 - S26
  • [37] Effect of zoledronic acid (ZOL) 5 mg on fracture risk by age and geographic region in women with postmenopausal osteoporosis: Results from horizon-PFT
    Cauley, J. A.
    Adachi, J.
    Cosman, F.
    Black, D.
    Boonen, S. R.
    Cummings, S.
    Delmas, P.
    Eastell, R.
    [J]. BONE, 2007, 40 (06) : S132 - S132
  • [38] Role of zoledronic acid in the prevention and treatment of osteoporosis
    Rakel, Agnes
    Boucher, Andree
    Ste-Marie, Louis-Georges
    [J]. CLINICAL INTERVENTIONS IN AGING, 2011, 6 : 89 - 99
  • [39] Zoledronic acid infusion for prevention and treatment of osteoporosis
    Sunyecz, John A.
    [J]. INTERNATIONAL JOURNAL OF WOMENS HEALTH, 2010, 2 : 353 - 360
  • [40] Effect of Once-Yearly Zoledronic Acid 5 mg Infusion on Fracture Incidence in Postmenopausal Osteoporosis: Subgroup Analysis of the Horizon PFT Study
    Eastell, R.
    Black, D. M.
    Boonen, S.
    Cummings, S. R.
    Delmas, P. D.
    Palermo, L.
    Mesenbrink, P.
    Cauley, J. A.
    [J]. JOURNAL OF BONE AND MINERAL RESEARCH, 2008, 23 : S9 - S9
12345